secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001140361-25-007340
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Anteris Technologies appoints David St Denis as President and Class II director
-------------------------------------------------------------------------------

- Appointment effective March 5, 2025; St Denis retains COO role and serves as CEO of v2vmedtech.
- St Denis has been COO since July 2017; prior roles include Merck and Millennium Pharmaceuticals.
- No material amendment to compensatory arrangements; no new grants or awards in connection.
- St Denis will not sit on any Board committees due to non-independent status.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125007340/0001140361-25-007340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125007340/ef20045020_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-007340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer